Sensyne signs £0.5m Covid-19 test deal with DHSC
Clinical artificial intelligence (AI) technology company Sensyne Health has signed a £0.47m agreement with the Department of Health and Social Care, it announced on Friday, to conduct the second stage of a pilot study of its ‘MagnifEye’ technology for use with Covid-19 lateral flow diagnostic tests.
The AIM-traded firm said the agreement followed the signing of an exclusive licence and development agreement with Excalibur Healthcare Services on 9 February, to apply MagnifEye for use with lateral flow rapid diagnostic tests.
“We are delighted to be working with the Department of Health and Social Care and Excalibur, and are happy to be able to contribute to the UK's Covid-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests,” said chief executive officer Lord Drayson.
“[We] look forward to the results of this pilot study.”
At 0840 GMT, shares in Sensyne Health were up 4.32% at 175.25p.